Holen Sie sich die Stockscreener-App
23.65
1.20%
0.28
Vorhandelsmarkt:
23.81
0.16
+0.68%
Schlusskurs vom Vortag:
$23.37
Offen:
$23.48
24-Stunden-Volumen:
1.69M
Relative Volume:
0.47
Marktkapitalisierung:
$1.90B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-96.66M
KGV:
-11.00
EPS:
-2.15
Netto-Cashflow:
$-83.73M
1W Leistung:
-10.21%
1M Leistung:
-15.78%
6M Leistung:
+417.51%
1J Leistung:
+353.07%
1-Tages-Spanne:
$22.40
$23.78
1-Wochen-Bereich:
$22.40
$27.13
52-Wochen-Spanne:
$2.86
$36.26
Olema Pharmaceuticals Inc Stock (OLMA) Company Profile
Firmenname
Olema Pharmaceuticals Inc
Sektor
Branche
Telefon
(415) 651-3316
Adresse
780 BRANNAN STREET, SAN FRANCISCO
Compare OLMA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OLMA
Olema Pharmaceuticals Inc
|
23.65 | 1.87B | 0 | -96.66M | -83.73M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.24 | 117.59B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
778.97 | 79.81B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
834.55 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.28 | 42.67B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
351.27 | 39.11B | 4.98B | 69.60M | 525.67M | 0.5198 |
Olema Pharmaceuticals Inc Stock (OLMA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-11 | Eingeleitet | Stifel | Buy |
| 2026-01-07 | Eingeleitet | Piper Sandler | Overweight |
| 2025-10-08 | Eingeleitet | Guggenheim | Buy |
| 2025-08-12 | Bestätigt | Citigroup | Buy |
| 2024-04-02 | Eingeleitet | Goldman | Buy |
| 2024-01-30 | Eingeleitet | Citigroup | Buy |
| 2023-07-21 | Eingeleitet | Oppenheimer | Outperform |
| 2023-05-05 | Eingeleitet | CapitalOne | Overweight |
| 2023-02-22 | Eingeleitet | Credit Suisse | Outperform |
| 2022-07-06 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-06-09 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2022-02-28 | Eingeleitet | H.C. Wainwright | Neutral |
| 2021-12-07 | Fortgesetzt | Cowen | Outperform |
| 2020-12-14 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-12-14 | Eingeleitet | Cowen | Outperform |
| 2020-12-14 | Eingeleitet | JP Morgan | Overweight |
| 2020-12-14 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Olema Pharmaceuticals Inc Aktie (OLMA) Neueste Nachrichten
This Olema Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday - Benzinga
Stifel Initiates Coverage on Olema Pharmaceuticals (OLMA) with B - GuruFocus
Olema Pharmaceuticals (NASDAQ:OLMA) Now Covered by Analysts at Stifel Nicolaus - MarketBeat
Stifel Nicolaus Initiates Coverage on Olema Pharmaceuticals With Buy Rating - marketscreener.com
Candriam S.C.A. Increases Stock Position in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Will Olema Pharmaceuticals Inc. stock benefit from automationJuly 2025 Closing Moves & Weekly High Return Stock Opportunities - mfd.ru
Stifel initiates Olema Pharmaceuticals stock with Buy rating, $48 target By Investing.com - Investing.com Canada
Olema Pharmaceuticals, Inc. Rings the Closing Bell - Nasdaq
Olema Oncology to Participate in Upcoming Investor Conferences - Sahm
Olema Pharmaceuticals seeks NDA lead for biotech program - Traders Union
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Weekly Recap: Does Olema Pharmaceuticals Inc have pricing power2025 Key Highlights & High Conviction Trade Alerts - baoquankhu1.vn
Institutional Investors Control 63% of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) and Were Rewarded Last Week After Stock Increased 7.2% - 富途牛牛
Cancer index surges 72% as Terns, Olema lead gains - BioWorld MedTech
Investment Review: Is Olema Pharmaceuticals Inc stock trending bullishQuarterly Trade Summary & Consistent Return Strategy Ideas - baoquankhu1.vn
Olema Pharmaceuticals to Present at Upcoming Investor Conferences in February 2026 - Quiver Quantitative
Breast cancer drug developer Olema lines up three investor talks - Stock Titan
Risks Report: Whats next for Olema Pharmaceuticals Inc stockJuly 2025 Setups & Growth Focused Investment Plans - baoquankhu1.vn
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Short Interest in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Decreases By 12.5% - MarketBeat
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Gap DownTime to Sell? - MarketBeat
A Look At Olema Pharmaceuticals (OLMA) Valuation After Renewed Buy Ratings And Phase 3 Breast Cancer Plans - Sahm
Breakout Zone: How much upside does Olema Pharmaceuticals Inc haveJuly 2025 Market Mood & Accurate Buy Signal Alerts - baoquankhu1.vn
Trend Recap: What are analysts price targets for Olema Pharmaceuticals IncEarnings Miss & Fast Moving Stock Watchlists - baoquankhu1.vn
Olema Oncology CFO Shane Kovacs to depart after six-year tenure By Investing.com - Investing.com India
Olema CFO Exit Puts Focus On Palazestrant Plans And Cash Discipline - Yahoo Finance
Olema Oncology CFO Shane Kovacs to depart after six-year tenure - Investing.com Australia
Olema Pharmaceuticals CFO Shane Kovacs departs, CEO assumes interim finance role By Investing.com - Investing.com Nigeria
Olema Pharmaceuticals CFO Shane Kovacs departs, CEO assumes interim finance role - Investing.com Nigeria
Olema Pharmaceuticals stock falls after CFO announces departure By Investing.com - Investing.com South Africa
Olema Pharmaceuticals stock falls after CFO announces departure - Investing.com
Olema Pharmaceuticals (OLMA) Executive Leadership Shift - GuruFocus
Olema Pharmaceuticals CFO Departs; CEO Assumes Interim Role - TipRanks
Olema Pharmaceuticals Chief Operating and Financial Officer Shane Kovacs Departs - marketscreener.com
Olema Oncology Announces Departure of Chief Operating and Financial Officer - The Manila Times
Olema (NASDAQ: OLMA) CFO exits with $621,283 package as CEO steps in - Stock Titan
Olema Oncology announces departure of chief operating and financial officer - marketscreener.com
Breast cancer-focused Olema sees financial officer depart, CEO steps in - stocktitan.net
LifeSci Capital Reiterates a Buy on Olema Pharmaceuticals (OLMA) - Finviz
10 Best Small-Cap Stocks Ready to Explode in 2026 - Insider Monkey
Olema Pharmaceuticals (OLMA) stock jumps 6% in a weak market — what to watch next - TechStock²
Olema Pharmaceuticals (NASDAQ:OLMA) Trading 7.7% HigherHere's What Happened - MarketBeat
Should I invest in Olema Pharmaceuticals Inc. before earningsGap Down & High Conviction Trade Alerts - mfd.ru
SEC Enforcement Action Targets Insider Trading in the Pharmaceutical Industry - akingump.com
Aug Outlook: Does Olema Pharmaceuticals Inc have pricing power2025 Geopolitical Influence & High Conviction Trade Alerts - baoquankhu1.vn
Apellis, Olema, Exicure, Immunovant, LivePerson Insider Shake-Up - TipRanks
Harmon Cyrus, director at Olema, sells $268,800 in stock By Investing.com - Investing.com UK
Olema Pharmaceuticals (NASDAQ:OLMA) Director Cyrus Harmon Sells 10,000 Shares - MarketBeat
Harmon Cyrus, director at Olema, sells $268,800 in stock - Investing.com
Finanzdaten der Olema Pharmaceuticals Inc-Aktie (OLMA)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.09%
2.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):